The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.
Paroxetine results in increased activity of and results in increased cleavage of CASP3 protein Paroxetine results in increased activity of CASP3 protein
isoliquiritigenin inhibits the reaction [Paroxetine results in decreased activity of CAT protein]; Sildenafil Citrate inhibits the reaction [Paroxetine results in decreased activity of CAT protein]
Paroxetine inhibits the reaction [CYP2B6 protein results in increased chemical synthesis of hydroxybupropion]; Paroxetine inhibits the reaction [CYP2B6 protein results in increased metabolism of Bupropion] Paroxetine results in decreased activity of CYP2B6 protein
CYP2D6 gene mutant form results in decreased metabolism of Paroxetine CYP2D6 gene mutant form results in increased susceptibility to Paroxetine CYP2D6 protein results in increased metabolism of Paroxetine [Paroxetine results in decreased activity of CYP2D6 protein] which results in decreased abundance of 4-hydroxy-N-desmethyltamoxifen; [Paroxetine results in decreased activity of CYP2D6 protein] which results in decreased degradation of Metoprolol; [Paroxetine results in decreased activity of CYP2D6 protein] which results in decreased metabolism of Dextromethorphan; [Paroxetine results in decreased activity of CYP2D6 protein] which results in increased susceptibility to Metoprolol; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in decreased susceptibility to Debrisoquin]; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in decreased susceptibility to Nortriptyline]; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in increased abundance of 10-hydroxynortriptyline]; Paroxetine inhibits the reaction [CYP2D6 gene mutant form results in increased abundance of Debrisoquin metabolite]; Paroxetine inhibits the reaction [CYP2D6 protein results in increased chemical synthesis of Dextrorphan]; Paroxetine inhibits the reaction [CYP2D6 protein results in increased metabolism of Dextromethorphan]; Paroxetine inhibits the reaction [CYP2D6 protein results in increased oxidation of dimemorfan]
[[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein
Paroxetine results in increased activity of GPT protein isoliquiritigenin inhibits the reaction [Paroxetine results in increased activity of GPT protein]; Sildenafil Citrate inhibits the reaction [Paroxetine results in increased activity of GPT protein]
[[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; [Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein; Paroxetine binds to and results in increased activity of HTR2C protein
Paroxetine results in increased expression of IL10 mRNA; Paroxetine results in increased expression of IL10 protein LY 215840 inhibits the reaction [Paroxetine results in increased expression of IL10 mRNA]; LY 215840 inhibits the reaction [Paroxetine results in increased expression of IL10 protein]
Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]; pyrazolanthrone inhibits the reaction [Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]]
Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]; pyrazolanthrone inhibits the reaction [Paroxetine affects the reaction [INS protein affects the phosphorylation of IRS1 protein]] Paroxetine results in decreased activity of IRS1 protein
Paroxetine results in decreased activity of [KCNJ3 protein binds to KCNJ6 protein]; Paroxetine results in decreased activity of [KCNJ6 protein binds to KCNJ5 protein]; Paroxetine results in decreased activity of [KCNJ6 protein binds to KCNJ6 protein]
[[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein
[[Paroxetine binds to and results in increased activity of HTR2C protein] which results in increased phosphorylation of and results in increased activity of EGFR protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein
Paroxetine results in increased activity of MAPK8 protein pyrazolanthrone inhibits the reaction [Paroxetine results in increased phosphorylation of and results in increased activity of MAPK8 protein]
Paroxetine results in decreased expression of SLC6A4 mRNA Paroxetine affects the expression of SLC6A4 mRNA Paroxetine binds to and results in decreased activity of SLC6A4 protein
Paroxetine results in decreased expression of STAT3 mRNA; Paroxetine results in decreased expression of STAT3 protein LY 215840 promotes the reaction [Paroxetine results in increased expression of STAT3 mRNA]
Paroxetine results in decreased secretion of TNF protein Paroxetine results in decreased expression of TNF protein LY 215840 inhibits the reaction [Paroxetine results in decreased expression of TNF protein]
browse the term
